Joseph Chiesa

Covance (United Kingdom) — United Kingdom

Medicine · Health Sciences

7h-index1.9kcitations12works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(3), Alzheimer's disease research and treatments(2), Advanced biosensing and bioanalysis techniques(2), RNA Interference and Gene Delivery(2), Amyloidosis: Diagnosis, Treatment, Outcomes(2)

Publications12 total

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers
Antimicrobial Agents and Chemotherapy·2017· 3 citedOpen Access
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Molecular Therapy·2017· 202 citedOpen Access
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
Alzheimer s & Dementia Translational Research & Clinical Interventions·2015· 54 citedOpen Access
Featured Article A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
2015
Abstract 11889: Phase Ib Study of Icosabutate, a Novel Structurally Enhanced Fatty Acid, in Subjects With Hypercholesterolemia
Circulation·2014· 6 cited
Safety, pharmacokinetics, pharmacogenomics and <scp>QT</scp> concentration−effect modelling of the <scp>SirT1</scp> inhibitor selisistat in healthy volunteers
British Journal of Clinical Pharmacology·2014· 58 citedOpen Access
A first in human study to investigate the safety, tolerability and pharmacokinetics of single and multiple doses of SMT19969 in male healthy subjects
2014
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
The Lancet·2013· 571 citedOpen Access
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
New England Journal of Medicine·2013· 947 citedOpen Access
Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC)
Journal of Cardiac Failure·2013· 16 cited
Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia
Arteriosclerosis Thrombosis and Vascular Biology·2012· 13 cited
QT effect of semagacestat at therapeutic and supratherapeutic doses
International Journal of Clinical Pharmacology and Therapeutics·2012· 2 cited

Frequent Co-authors

Akshay Vaishnaw(5), Renta Hutabarat(4), Saraswathy V. Nochur(4), Jared Gollob(4), Verena Karsten(4), Timothy Mant(3), Jeffrey Cehelsky(3), Brian R. Bettencourt(3), Valerie A. Clausen(3), Kevin Fitzgerald(3), Malathy Munisamy(2), Rick Falzone(2), Jamie Harrop(2), Maria Frank-Kamenetsky(2), Jessica E. Sutherland(2), James M. Ritter(2), Amy Simon(2), Tracy Zimmermann(2), Amy Chan(2), Inge Lues(2)